Search Clinical Trials
Withdrawn
Azacytidine During Anti-tuberculosis Therapy (External Link)
All study participants will have drug-sensitive TB and successfully complete 2 months of standard intensive phase 4-drug RHZE (rifampin, isoniazid, pyrazinamide, ethambutol). By definition, to have uncomplicated TB, participants will …
Withdrawn
Nitric Oxide During CPB to Reduce AKI in Neonates (External Link)
Screening: All patients undergoing either elective or emergency cardiac surgery will be screened against the eligibility criteria. Research Sample Collection: Blood and urine will be collected for the first 48 …
Withdrawn
Peppermint Oil Pharmacokinetics/Dynamics (External Link)
An initial single-dose PK study will be carried out. Forty-two children (n=21 per dose) will be randomized to receive approximately 10.9 mg·kg-1·d-1 of PMO or to receive approximately 18.2 mg·kg-1·d-1 …
Baylor Role:
Lead Sponsor
Withdrawn
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (External Link)
A maximum of 42 subjects will participate in the treatment part of this study. The investigators will collect up to 180 mL of the participants blood. The investigators will use …
Baylor Role:
Lead Sponsor
Withdrawn
Zonisamide Outpatient Study (External Link)
This is a randomized, double-blind, placebo-controlled study to examine the ability of 5-weeks treatment with zonisamide to reduce symptoms of PTSD and AUD. The study population will consist of 60 …
Baylor Role:
Collaborator
Withdrawn
Tranexamic Acid in Adherent Placenta (TAP) (External Link)
This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in …
Baylor Role:
Lead Sponsor
Withdrawn
Safe Return and Disposal of Unused Opioids (External Link)
Participants identified by the PI and participating research staff/coordinators that will receive opioids following discharge will be approached. The participant information sheet will be provided to the parents/legal guardian and …
Baylor Role:
Lead Sponsor
Withdrawn
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA (External Link)
To prepare the neuroblastoma specific Natural Killer T cells (also called GINAKIT cells), about 80 mL (up to 6 tablespoons) of blood will be collected from the patient. For children, …
Baylor Role:
Lead Sponsor
Withdrawn
Trial- Dysphagia From ETT or GI Endoscopy (External Link)
Patients between the ages of 5-17 with normal cognitive function presenting for Upper GI endoscopy will be considered for participation in this study. After consent is obtained from the parent/legal …
Baylor Role:
Lead Sponsor
Withdrawn
H-36731: Finasteride in Management of Elevated Red Blood Cells (External Link)
Hypogonadism is becoming an increasingly recognized clinical syndrome affecting millions of men in the United States and globally, and is characterized by symptoms including chronic fatigue, decreased libido and muscle …
Baylor Role:
Lead Sponsor